Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS Gains 5%; BSE HEALTHCARE Index Up 0.5%
Tue, 27 Aug 9:30

SYNCOM FORMULATIONS Gains 5%; BSE HEALTHCARE Index Up 0.5%Image source: hudiemm/www.istockphoto.com

SYNCOM FORMULATIONS share price has zoomed 5% and is presently trading at Rs 21.6.

Meanwhile, the BSE HEALTHCARE index is at 42,354.4 (up 0.5%).

Among the top gainers in the BSE HEALTHCARE index today are J.B.Chemicals (up 4.4%) and AARTI DRUGS (up 2.1%).

GSK Pharma (down 0.8%) and ASTER DM HEALTHCARE (down 0.7%) are among the top losers today.

Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 9.0 to Rs 21.6, registering a gain of Rs 12.6 (up 140.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,099.5 to 42,354.4, registering a gain of 50.7% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 131.0%), Glenmark Pharma (up 125.0%) and SUVEN PHARMACEUTICALS (up 108.6%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,736.9 .

The top gainers among the BSE Sensex today are HCl Tech. (up 1.9%) and Power Grid Corp. (up 0.9%). The most traded stocks in the BSE Sensex are Tata Steel and HCl Tech..

In the meantime, NSE Nifty is at 25,017.7 . HCl Tech. and Bajaj Finserv are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,433.3 to 81,736.9, registering a gain of 16,303.6 points (up 24.9%).

SYNCOM FORMULATIONS Financial Update...

SYNCOM FORMULATIONS net profit grew 73.6% YoY to Rs 76 million for the quarter ended June 2024, compared to a profit of Rs 44 million a year ago. Net sales rose 45.8% to Rs 873 million during the period as against Rs 598 million in April-June 2023.

For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.

The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 71.1.


Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 5%; BSE HEALTHCARE Index Up 0.5%". Click here!